160 related articles for article (PubMed ID: 38044648)
1. Research progress in cuproptosis in liver cancer.
Chen L; Liu D; Tan Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Sept 28; 48(9):1368-1376. PubMed ID: 38044648
[TBL] [Abstract][Full Text] [Related]
2. Cuproptosis as the new kryptonite of cancer: a copper-dependent novel cell death mechanism with promising implications for the treatment of hepatocellular carcinoma.
Ozkan E; Bakar-Ates F
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17663-17670. PubMed ID: 37843555
[TBL] [Abstract][Full Text] [Related]
3. Identification of a prognostic cuproptosis-related signature in hepatocellular carcinoma.
Chen Y; Tang L; Huang W; Abisola FH; Zhang Y; Zhang G; Yao L
Biol Direct; 2023 Feb; 18(1):4. PubMed ID: 36750831
[TBL] [Abstract][Full Text] [Related]
4. The Role of Ferroptosis and Cuproptosis in Curcumin against Hepatocellular Carcinoma.
Liu Z; Ma H; Lai Z
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838613
[TBL] [Abstract][Full Text] [Related]
5. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
Liu Y; Jiang J
Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
[TBL] [Abstract][Full Text] [Related]
6. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
7. Identification of cuproptosis-related subtypes, cuproptosis-related gene prognostic index in hepatocellular carcinoma.
Ding L; Li W; Tu J; Cao Z; Li J; Cao H; Liang J; Liang Y; Yu Q; Li G
Front Immunol; 2022; 13():989156. PubMed ID: 36177029
[TBL] [Abstract][Full Text] [Related]
8. Deep learning enables the discovery of a novel cuproptosis-inducing molecule for the inhibition of hepatocellular carcinoma.
Yang F; Jia L; Zhou HC; Huang JN; Hou MY; Liu FT; Prabhu N; Li ZJ; Yang CB; Zou C; Nordlund P; Wang JG; Dai LY
Acta Pharmacol Sin; 2024 Feb; 45(2):391-404. PubMed ID: 37803139
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
[TBL] [Abstract][Full Text] [Related]
10. DLAT as a Cuproptosis Promoter and a Molecular Target of Elesclomol in Hepatocellular Carcinoma.
Gao F; Yuan Y; Ding Y; Li PY; Chang Y; He XX
Curr Med Sci; 2023 Jun; 43(3):526-538. PubMed ID: 37286711
[TBL] [Abstract][Full Text] [Related]
11. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma.
Yan C; Niu Y; Ma L; Tian L; Ma J
J Transl Med; 2022 Oct; 20(1):452. PubMed ID: 36195876
[TBL] [Abstract][Full Text] [Related]
12. Construction and systematic evaluation of a machine learning-based cuproptosis-related lncRNA score signature to predict the response to immunotherapy in hepatocellular carcinoma.
Lu D; Liao J; Cheng H; Ma Q; Wu F; Xie F; He Y
Front Immunol; 2023; 14():1097075. PubMed ID: 36761763
[TBL] [Abstract][Full Text] [Related]
13. Copper metabolism-related risk score identifies hepatocellular carcinoma subtypes and SLC27A5 as a potential regulator of cuproptosis.
Li X; Wang J; Guo Z; Ma Y; Xu D; Fan D; Dai P; Chen Y; Liu Q; Jiao J; Fan J; Wu N; Li X; Li G
Aging (Albany NY); 2023 Dec; 15(24):15084-15113. PubMed ID: 38157255
[TBL] [Abstract][Full Text] [Related]
14. Copper homeostasis and cuproptosis in mitochondria.
Tian Z; Jiang S; Zhou J; Zhang W
Life Sci; 2023 Dec; 334():122223. PubMed ID: 38084674
[TBL] [Abstract][Full Text] [Related]
15. The molecular mechanisms of cuproptosis and its relevance to cardiovascular disease.
Wang D; Tian Z; Zhang P; Zhen L; Meng Q; Sun B; Xu X; Jia T; Li S
Biomed Pharmacother; 2023 Jul; 163():114830. PubMed ID: 37150036
[TBL] [Abstract][Full Text] [Related]
16. A prognostic signature of cuproptosis and TCA-related genes for hepatocellular carcinoma.
Zhang Q; Ma L; Zhou H; Zhou Y; Liu S; Li Q
Front Oncol; 2022; 12():1040736. PubMed ID: 36324575
[TBL] [Abstract][Full Text] [Related]
17. Novel Molecular Subtyping Scheme Based on In Silico Analysis of Cuproptosis Regulator Gene Patterns Optimizes Survival Prediction and Treatment of Hepatocellular Carcinoma.
Jiang H; Chen H; Wang Y; Qian Y
J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762710
[TBL] [Abstract][Full Text] [Related]
18. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
Wang S; Bai H; Fei S; Miao B
Biochem Genet; 2023 Oct; ():. PubMed ID: 37898914
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma.
Tang X; Ren X; Huang T; Miao Y; Ha W; Li Z; Yang L; Mi D
Mediators Inflamm; 2023; 2023():3951940. PubMed ID: 37124062
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis of cuproptosis-related lncRNAs for prognostic significance and immune microenvironment characterization in hepatocellular carcinoma.
Li D; Jin S; Chen P; Zhang Y; Li Y; Zhong C; Fan X; Lin H
Front Immunol; 2022; 13():991604. PubMed ID: 36685508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
